Eptinezumab-Jjmr
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Drug-induced headache reports: a comprehensive disproportionality and time-to-onset pharmacovigilance study using the FAERS database (2018-2024).
Journal: Frontiers in pain research (Lausanne, Switzerland)
Published: July 21, 2025
Zavegepant (Zavzpret) for acute treatment of migraine.
Journal: The Medical letter on drugs and therapeutics
Published: July 17, 2023
Treatment with eptinezumab for migraine prevention in people with chronic migraine and medication-overuse headache: a plain language summary.
Journal: Pain management
Published: June 26, 2023
Comparison table: Some drugs for migraine prevention in adults.
Journal: The Medical letter on drugs and therapeutics
Published: June 02, 2023
Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults.
Journal: Health psychology research
Published: November 16, 2022
Atogepant (Qulipta) for migraine prevention.
Journal: The Medical letter on drugs and therapeutics
Published: January 27, 2022
In brief: Hypertension with erenumab (Aimovig).
Journal: The Medical letter on drugs and therapeutics
Published: April 08, 2021
Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention.
Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention.
Journal: SAGE open medicine
Published: March 15, 2021
Eptinezumab (Vyepti) for migraine prevention.
Journal: The Medical letter on drugs and therapeutics
Published: June 20, 2020
Last Updated: 02/24/2026